Anu Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 4.95 M
- Company Age 23 Year, 10 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 3.07 Cr
- Revenue Growth -99.87%
- Profit Growth 99.46%
- Ebitda 99.90%
- Net Worth -0.37%
- Total Assets -59.63%
About Anu Pharma
Anu Pharma Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 March 2001 and has a history of 23 years and ten months. Its registered office is in Medak, Telangana, India.
The Corporate was formerly known as Anu's Pharma Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 4.95 M.
The company currently has active open charges totaling ₹3.07 Cr.
Narayana Prathivada, Buthuru Shastry, and Chandramohan Nampalli serve as directors at the Company.
Company Details
- Location
Medak, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232TG2001PTC036494
- Company No.
036494
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Mar 2001
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Anu Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narayana Prathivada  | Director | 16-Jan-2009 | Current |
| Buthuru Shastry | Additional Director | 03-May-2023 | Current |
| Chandramohan Nampalli | Additional Director | 03-May-2023 | Current |
Financial Performance of Anu Pharma.
Anu Pharma Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 99.87% decrease. The company also saw a substantial improvement in profitability, with a 99.46% increase in profit. The company's net worth dipped by a decrease of 0.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anu Pharma?
In 2019, Anu Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.07 Cr
₹0
Charges Breakdown by Lending Institutions
- Karnataka Bank Limited : 3.00 Cr
- The Karnataka Bank Limited : 0.07 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Apr 2012 | The Karnataka Bank Limited | ₹0.70 M | Open |
| 07 Mar 2011 | Karnataka Bank Limited | ₹3.00 Cr | Open |
How Many Employees Work at Anu Pharma?
Unlock and access historical data on people associated with Anu Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anu Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anu Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
